Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report

References

• Niebel D, de Vos L, Fetter T, Brägelmann C, Wenzel J. Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions. Am J Clin Dermatol. 2023;24(4):521–540. doi:10.1007/s40257-023-00774-8
   PubMed Web of Science ®Google Scholar
• Petersen MP, Möller S, Bygum A, Voss A, Bliddal M. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus. 2018;27(9):1424–1430. doi:10.1177/0961203318777103
   PubMed Web of Science ®Google Scholar
• Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335–1341. doi:10.1111/j.1365-2133.2011.10272.x
   PubMed Web of Science ®Google Scholar
• Worm M, Zidane M, Eisert L, et al. S2k guideline: diagnosis and management of cutaneous lupus erythematosus - Part 1: classification, diagnosis, prevention, activity scores. J Dtsch Dermatol Ges. 2021;19(8):1236–1247.
   Web of Science ®Google Scholar
• Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–381. doi:10.2165/11310780-000000000-00000
   PubMed Web of Science ®Google Scholar
• Mokhtari F, Ganjei Z. A rare form of discoid lupus erythematosus as a rosacea and angiofibroma: a case report. Clin Case Rep. 2020;8(1):155–158. doi:10.1002/ccr3.2611
   PubMed Web of Science ®Google Scholar
• Jisha K, Rajesh PS, Kurien G, Sathish G, Vijayamma N. Chronic blepharitis like picture in patients with Discoid lupus erythematosis - Case series. Nepal J Ophthalmol. 2017;9(18):175–179. doi:10.3126/nepjoph.v9i2.19264
   PubMedGoogle Scholar
• Goodfield MJD, Jones SK, Veale DJ. The ‘Connective Tissue Diseases’. In: Rook’s Textbook of Dermatology. John Wiley & Sons; 2010:1–138.
   Google Scholar
• Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol. 2016;17(2):135–146. doi:10.1007/s40257-016-0173-9
   PubMed Web of Science ®Google Scholar
• Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8(6):467–473. doi:10.1016/j.autrev.2008.12.014
   PubMed Web of Science ®Google Scholar
• Lu Q, Long H, Chow S, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. 2021;123:102707. doi:10.1016/j.jaut.2021.102707
   PubMed Web of Science ®Google Scholar
• Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389–404. doi:10.1111/jdv.14053
   PubMed Web of Science ®Google Scholar
• Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–532. doi:10.1038/s41584-019-0272-0
   PubMed Web of Science ®Google Scholar
• Kuhn A, Meuth AM, Bein D, et al. Revised cutaneous lupus erythematosus disease area and severity index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163(1):83–92. doi:10.1111/j.1365-2133.2010.09799.x
   PubMed Web of Science ®Google Scholar
• Sigges J, Biazar C, Landmann A, et al. Therapeutic strategies evaluated by the European society of cutaneous lupus erythematosus (EUSCLE) core set questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev. 2013;12(7):694–702. doi:10.1016/j.autrev.2012.10.005
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with Acitretin and hydroxychloroquine. Br J Dermatol. 1992;127(5):513–518. doi:10.1111/j.1365-2133.1992.tb14851.x
   PubMed Web of Science ®Google Scholar
• Yokogawa N, Eto H, Tanikawa A, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol. 2017;69(4):791–799. doi:10.1002/art.40018
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–28. doi:10.1136/ard.2008.101766
   PubMed Web of Science ®Google Scholar
• Fairley JL, Oon S, Saracino AM, Nikpour M. Management of cutaneous manifestations of lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2020;50(1):95–127. doi:10.1016/j.semarthrit.2019.07.010
   PubMed Web of Science ®Google Scholar
• Li CK, Baker K, Jones T, Coulson E, Roberts A, Birrell F. Safety and tolerability of subcutaneous methotrexate in routine clinical practice. Arthritis Care Res. 2021;73(9):1306–1311. doi:10.1002/acr.24334
   Web of Science ®Google Scholar
• Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10):e0164080. doi:10.1371/journal.pone.0164080
   PubMed Web of Science ®Google Scholar
• Fetter T, Smith P, Guel T, Braegelmann C, Bieber T, Wenzel J. Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions. Front Immunol. 2020;11:344. doi:10.3389/fimmu.2020.00344
   PubMed Web of Science ®Google Scholar
• Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2022;20:61–64. doi:10.1016/j.jdcr.2021.09.030
   PubMedGoogle Scholar
• You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi:10.1136/annrheumdis-2019-215455
   PubMed Web of Science ®Google Scholar
• Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi:10.1038/s41467-021-23361-z
   PubMed Web of Science ®Google Scholar
• Ananthan L, Williams M, Morgan H, Patel GK. Cutaneous lupus erythematosus variants responsive to Janus kinase inhibition. Dermatol Ther. 2022;35(12):e15967. doi:10.1111/dth.15967
   PubMed Web of Science ®Google Scholar
• Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, Phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1001–1010. doi:10.1016/S0140-6736(22)02607-1
   PubMedGoogle Scholar
• Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011–1019. doi:10.1016/S0140-6736(22)02546-6
   PubMedGoogle Scholar
• Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology. 2022;61(6):2413–2423. doi:10.1093/rheumatology/keab685
   PubMed Web of Science ®Google Scholar
• Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. 2016;136(6):1281–1283. doi:10.1016/j.jid.2016.02.015
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222–231. doi:10.1016/S0140-6736(18)31363-1
   PubMed Web of Science ®Google Scholar